

1 **Outbreak of a carbapenem-resistant XDR *Acinetobacter baumannii* belonging to**
2 **the International Clone II (IC2) in a clinical setting in Brazil, 2022**

3

4 Érica Lourenço da Fonseca^{1,*}, Sérgio Mascarenhas Morgado¹, Fernanda dos Santos
5 Freitas¹, Priscila P. C. Oliveira², Priscilla M. Monteiro², Lorena S. Lima², Bianca P.
6 Santos², Maria Aparecida R. Sousa², Adriana O. Assunção², Luís Affonso Mascarenhas²
7 and Ana Carolina Paulo Vicente¹

8

9 ¹ Instituto Oswaldo Cruz, Laboratório de Genética Molecular de Microrganismos,
10 FIOCRUZ, Rio de Janeiro, Brazil

11 ² Hospital Infection Control Committee, Hospital São Francisco na Providência de
12 Deus, Rio de Janeiro, Brazil

13

14 **Corresponding Author:** Érica L. Fonseca (ericafon@ioc.fiocruz.br)

15

16 **Keywords:** International clone; CRAB; extensively drug resistance; *armA*; OXA-23;
17 tigecycline resistance.

18

19

20

21

22 **ABSTRACT**

23 Carbapenem-resistant *Acinetobacter baumannii* (CRAB) is a leading cause of
24 nosocomial infections worldwide, and the occurrence of extensively drug-resistant
25 (XDR) lineages among them is increasing. Most of *A. baumannii* pandemic lineages,
26 known as International clones, are represented by MDR/XDR CRAB strains. The IC2 is
27 considered one of the most successful and widespread pandemic clones, however, it is
28 rare in South America, where IC1, IC4 and IC5 are prevalent. In Brazil, besides
29 sporadic reports, an IC2 outbreak was reported only once in São Paulo city during the
30 COVID-19 pandemics. This study characterized an outbreak caused by IC2 strains
31 (n=16) in a hospital in Rio de Janeiro in 2022. MLST (MLST Pasteur scheme) analysis
32 revealed that all strains recovered from nosocomial infections belonged to ST2 and
33 corresponded to CRAB presenting the XDR phenotype. In general, this broad resistance
34 spectrum was explained by the presence of several antibiotic resistance genes (ARGs)
35 (*armA*, *bla*_{TEM}, *bla*_{OXA-23}, *bla*_{OXA-66}, and *aacA4-catB8-aadA1-qacEΔ1/sul1* carried in
36 class 1 integron). Interestingly, the strains characterized here presented a broader
37 resistance spectrum compared to those of the unique other and contemporary IC2
38 outbreak in Brazil, although they shared most of the ARGs. This study stressed the
39 possibility of the successful establishment of IC2 in Brazilian clinical settings during
40 and after the COVID-19 pandemics in response to a series of events, such as the
41 overuse of antibiotics, during that period.

42

43

44

45

46 INTRODUCTION

47 *Acinetobacter baumannii* has emerged as one of the most critical opportunistic
48 pathogens for public health worldwide, being frequently involved in ventilator-
49 associated pneumonia, bacteremia, and life-threatening nosocomial infections among
50 severely ill and immunocompromised individuals [1]. This species belongs to the
51 ESKAPE group of pathogens and is featured by its propensity in persisting on inanimate
52 surfaces and acquiring multidrug resistance, which allows it to survive for long periods
53 in the hospital environment. These characteristics contribute to *A. baumannii* person-to-
54 person transmission, and nosocomial spread that favors the successful establishment of
55 infections, leading to a worrisome impact on clinical outcomes [2].

56 Currently, the golden standard for the treatment of infections caused by *A.*
57 *baumannii* is carbapenems due to their intrinsic activity against this pathogen [3]. High-
58 risk *A. baumannii* pandemic lineages, named international clones (ICs), generally
59 present a multidrug (MDR) and extensively drug resistance (XDR) character and have
60 been associated with outbreaks around the world. These lineages have mostly been
61 responsible for the spread of carbapenemase genes, such as *bla*_{OXA-23}, contributing
62 significantly to carbapenem resistance dispersion [4]. So far, several ICs have been
63 more frequently reported, and among them, the IC2 (represented by the ST2 determined
64 by the MLST Pasteur scheme) is the most globally disseminated and prevalent
65 carbapenem-resistant *A. baumannii* (CRAB) lineage that has been involved with
66 difficult-to-treat outbreaks around the world [5-8]. In Brazil, *A. baumannii* of IC1, IC4,
67 IC5 and to a lesser extent, IC7, have been the most prevalent international clones
68 circulating all over the country [9-14]. Moreover, the IC6 international clone
69 (ST78^{PAS}/ST944^{OXF}) was recently described in the Brazilian Amazon region [15].
70 However, in spite of the successful IC2 global spread, its occurrence has barely been

71 reported in Latin America [12,16]. Moreover, IC2 CRAB strains were sporadically
72 described in the Brazilian South region from 1999 to 2002, resurging after ten years
73 (2013-2014). After that, only more recently a local IC2 outbreak was reported in a
74 hospital in São Paulo city [17-21].

75 Here, we report a recent outbreak caused by CRAB of the IC2 lineage in a
76 hospital in Rio de Janeiro in 2022, and characterize the strains considering their
77 antimicrobial resistance profile, and the presence of genes and elements involved with
78 this phenotype.

79

80 **METHODS**

81 From June to September 2022, 16 *A. baumannii* strains were recovered from
82 nosocomial infections occurring in a tertiary care hospital placed in Rio de Janeiro. This
83 hospital has 250 beds of which 60 are divided into six ICUs, all of them with medical,
84 surgical and transplantation units. The bacteria were isolated from several clinical
85 specimens (blood, urine, and bronchoalveolar aspirate) of different inpatients placed in
86 the ICUs. Species identification was obtained by VITEK2 Automated System. The *A.*
87 *baumannii* identification was confirmed by PCR amplification and Sanger sequencing
88 of *cnp60*, and 16S rRNA genes.

89 The antimicrobial susceptibility test (AST) was determined by the disc-diffusion
90 method for all antibiotics considered for *Acinetobacter spp.* resistance classification
91 [22], and interpreted according to the Clinical and Laboratory Standards Institute
92 (CLSI) [23]. The Disc-diffusion method was also applied for tigecycline, but interpreted
93 to the breakpoints suggested by the FDA for *Enterobacteriaceae* (susceptible ≥ 19 mm;
94 intermediate 15–18 mm, and resistant ≤ 14 mm) (<https://>

95 www.accessdata.fda.gov/drugsatfda_docs/label/2013/021
96 821s026s0311bl.pdf) [24]. The MIC of polymyxin B and colistin was determined by
97 broth microdilution and interpreted according to the European Committee on
98 Antimicrobial Susceptibility Testing (EUCAST) guidelines (MIC breakpoints for
99 resistance >2mg/L) [25].

100 The Multilocus Sequence Typing (MLST) based on the Pasteur scheme (PAS)
101 [26] was performed to determine the strains' sequence typing (ST) and to establish their
102 clonal relationship (<https://pubmlst.org/organisms/acinetobacter-baumannii>). The
103 presence of the most frequent antimicrobial resistance genes involved with resistance
104 emergence to the clinically relevant antibiotics for *Acinetobacter spp.* [22] (*bla*_{IMP},
105 *bla*_{VIM}, *bla*_{NDM}, *bla*_{OXA-23}, *bla*_{OXA-24-like}, *bla*_{OXA-58-like}, *bla*_{OXA-51-like}, *bla*_{GES}, *bla*_{CTX-M},
106 *bla*_{TEM}, *armA*, *rmtD*, *mcr1-5*) were screened by PCR. The presence of IS*Aba1* upstream
107 *bla*_{OXA} genes was also evaluated. The Quinolone Resistance Determining Region
108 (QRDR) of *gyrA* and *parC* involved with fluoroquinolone resistance emergence in *A.*
109 *baumannii* was also investigated, as well as the class 1 and 2 integrons and their
110 antibiotic resistance gene content (Table 1).

111

112 **RESULTS AND DISCUSSION**

113 The MLST analysis revealed that all 16 strains belonged to the international
114 clone IC2. Interestingly, in spite of being a successfully worldwide established clone,
115 the IC2 is sparse and had not been associated with outbreaks in Brazil and South
116 America. After a long period without being detected in Brazil (last reported in 2014)
117 [20], CRAB IC2 resurged in 2020 causing an outbreak in a São Paulo hospital,
118 persisting for at least one year [21]. Interestingly, our study reports the contemporary

119 occurrence of an IC2 outbreak in another Southeast Brazilian state (Rio de Janeiro),
120 however, presenting a broader resistance profile compared with those IC2 strains of the
121 2020/2021 outbreak [21].

122 Our results revealed that, in general, all 16 strains presented the extensively drug
123 resistance (XDR) phenotype, with some slight differences in resistance pattern. They
124 were resistant to all cephalosporins and carbapenems, and susceptible to polymyxins
125 (Table 2). Interestingly, the tigecycline resistance profile was heterogeneous among
126 them (resistant=7; susceptible=9; intermediate=3), suggesting differential regulation of
127 genes involved with this resistance. Therefore, it is worth mentioning that despite the
128 XDR phenotype, these strains were treatable since, besides the polymyxins, some
129 strains were also susceptible to minocycline or tigecycline, which increases the chances
130 of favorable outcomes, mainly if these drugs are used in combination [27].

131 The PCR analyses revealed that most of the strains carried a class 1 integron
132 harbouring the *aacA4-catB8-aadA1-qacEΔ1/sul1* gene arrangement, which could
133 contribute to aminoglycoside resistance (*aacA4* and *aadA1*). Besides, the search for
134 ARGs revealed the presence of other genes conferring resistance to aminoglycosides
135 (*armA*), β-lactams (*bla_{TEM}*), and carbapenems (*bla_{OXA-23}* and the *bla_{OXA-51}* variant,
136 *bla_{OXA-66}*) in all studied ST2 *A. baumannii* (Table 2). All strains harboured the IS*AbaI*
137 upstream *bla_{OXA-23}*, which contributed to OXA-23 overexpression. This result
138 demonstrates the important role of *A. baumannii* international clones in OXA-23 and
139 carbapenem resistance dissemination throughout Brazil. Interestingly, IC2 strains
140 incriminated in recent outbreaks among inpatients infected with SARS-CoV-2 in Brazil
141 and Italy [21,28] shared most of the ARGs identified here (*aacA4*, *aadA1*, *catB8*, *armA*,
142 *bla_{OXA-23}* and *bla_{OXA-66}*), indicating that, although transferable, these genes may be well
143 established in the current IC2 lineage circulating worldwide. Moreover, all IC2 strains

144 harboured the Ser83Leu and Ser80Leu substitutions in the GyrA and ParC, respectively,
145 explaining the observed fluoroquinolone resistance.

146 Camargo *et al.* [21] suggested that the reemergence and occurrence of an IC2
147 outbreak in São Paulo could be attributed to several unprecedented factors resulting
148 from COVID-19 pandemics, such as the overuse of antibiotics, the high number of
149 inpatients undergoing invasive procedures, such as mechanical ventilation, and drastic
150 alterations in the hospital routine and infrastructure. This was also the case in the
151 studied hospital, and such factors could also have favored the emergence of the IC2
152 outbreak and the establishment of this international clone in Rio de Janeiro in the
153 COVID-19 post-pandemic period.

154 Therefore, the present study reported the current occurrence of the CRAB IC2
155 presenting the XDR phenotype causing an outbreak in a clinical setting in Rio de
156 Janeiro hospital. The expressive ARG set observed in these strains could impact the
157 overall resistance profile of the bacteria circulating in this hospital, due to the possibility
158 of horizontal transfer of these ARGs.

159

160 **FUNDING INFORMATION**

161 This study was supported by Conselho Nacional de Desenvolvimento Científico
162 e Tecnológico (CNPq) and Oswaldo Cruz Institute Grants.

163

164 **AUTHORS'S CONTRIBUTION**

165 Conceptualization, ELF and ACPV; formal analysis, ELF; Collection of data and
166 clinical samples, LAM, PPCO, PMO, LSL, BPS, MARS and AOA; methodology, FSF,

167 NMSB and SMM; writing – original draft, ELF; writing – review and editing, ELF and
168 ACPV; supervision, ACPV.

169

170 **CONFLICTS OF INTEREST**

171 The authors declare that there are no conflicts of interest.

172

173 **ETHICAL STATEMENT**

174 Ethics committee of FIOCRUZ gave ethical approval for this work under the number
175 39978114.5.0000.5248.

176

177 **REFERENCES**

- 178 1. **Appaneal HJ, Lopes VV, LaPlante KL, Caffrey AR.** Treatment, Clinical
179 Outcomes, and Predictors of Mortality among a National Cohort of Admitted Patients
180 with *Acinetobacter baumannii* Infection. *Antimicrob Agents Chemother*
181 2022;66:e0197521.
- 182 2. **Zarrilli R, Pournaras S, Giannouli M, Tsakris A.** Global evolution of multidrug-
183 resistant *Acinetobacter baumannii* clonal lineages. *Int J Antimicrob Agents*
184 2013;41:11-19.
- 185 3. **Fragkou PC, Poulakou G, Blizou A, Blizou M, Rapti V et al.** The Role of
186 Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug,
187 Extensively Drug and Pandrug Resistant *Acinetobacter baumannii*: A Systematic
188 Review of Clinical Evidence. *Microorganisms* 2019;7:159.

- 189 4. **Karah N, Khalid F, Wai SN, Uhlin BE, Ahmad I.** Molecular epidemiology and
190 antimicrobial resistance features of *Acinetobacter baumannii* clinical isolates from
191 Pakistan. *Ann Clin Microbiol Antimicrob* 2020;19:2.
- 192 5. **Trebosc V, Gartenmann S, Tötzl M, Lucchini V, Schellhorn B et al.** Dissecting
193 Colistin Resistance Mechanisms in Extensively Drug-Resistant *Acinetobacter*
194 *baumannii* Clinical Isolates. *mBio* 2019;10:e01083-19.
- 195 6. **Palmieri M, D'Andrea MM, Pelegrin AC, Perrot N, Mirande C et al.** Abundance
196 of Colistin-Resistant, OXA-23- and ArmA-Producing *Acinetobacter baumannii*
197 Belonging to International Clone 2 in Greece. *Front Microbiol* 2020;11:668.
- 198 7. **Khuntayaporn P, Kanathum P, Houngsaitong J, Montakantikul P,**
199 **Thirapanmethee K et al.** Predominance of international clone 2 multidrug-resistant
200 *Acinetobacter baumannii* clinical isolates in Thailand: a nationwide study. *Ann Clin*
201 *Microbiol Antimicrob* 2021;20:19.
- 202 8. **Pascale R, Bussini L, Gaibani P, Bovo F, Fornaro G et al.** Carbapenem-resistant
203 bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19)
204 pandemic: A multicenter before-and-after cross-sectional study. *Infect Control Hosp*
205 *Epidemiol* 2022;43:461-466.
- 206 9. **Caldart RV, Fonseca EL, Freitas F, Rocha L, Vicente AC.** *Acinetobacter*
207 *baumannii* infections in Amazon Region driven by extensively drug resistant
208 international clones, 2016-2018. *Mem Inst Oswaldo Cruz* 2019;114:e190232.
- 209 10. **Fonseca É, Freitas F, Caldart R, Morgado S, Vicente AC.** Pyomelanin
210 biosynthetic pathway in pigment-producer strains from the pandemic *Acinetobacter*
211 *baumannii* IC-5. *Mem Inst Oswaldo Cruz* 2020;115:e200371.

- 212 11. **Camargo CH, Cunha MPV, de Barcellos TAF, Bueno MS, Bertani AMJ et al.**
213 Genomic and phenotypic characterisation of antimicrobial resistance in carbapenem-
214 resistant *Acinetobacter baumannii* hyperendemic clones CC1, CC15, CC79 and CC25.
215 *Int J Antimicrob Agents* 2020;56:106195.
- 216 12. **Nodari CS, Cayô R, Streling AP, Lei F, Wille J et al.** Genomic Analysis of
217 Carbapenem-Resistant *Acinetobacter baumannii* Isolates Belonging to Major Endemic
218 Clones in South America. *Front Microbiol* 2020;11:584603.
- 219 13. **Nodari CS, Fuchs SA, Xanthopoulou K, Cayô R, Seifert H et al.** pmrCAB
220 Recombination Events among Colistin-Susceptible and -Resistant *Acinetobacter*
221 *baumannii* Clinical Isolates Belonging to International Clone 7. *mSphere*
222 2021;6:e0074621.
- 223 14. **Barcelos Valiatti T, Silva Carvalho T, Fernandes Santos F, Silva Nodari C,**
224 **Cayô R et al.** Spread of multidrug-resistant *Acinetobacter baumannii* isolates
225 belonging to IC1 and IC5 major clones in Rondônia state. *Braz J Microbiol*
226 2022;53:795-799.
- 227 15. **Fonseca ÉL, Caldart RV, Freitas FS, Morgado SM, Rocha LT et al.** Emergence
228 of extensively drug-resistant international clone IC-6 *Acinetobacter baumannii*
229 carrying blaOXA-72 and blaCTX-M-115 in the Brazilian Amazon region. *J Glob*
230 *Antimicrob Resist* 2020;20:18-21.
- 231 16. **Levy-Blitchein S, Roca I, Plasencia-Rebata S, Vicente-Taboada W, Velásquez-**
232 **Pomar J et al.** Emergence and spread of carbapenem-resistant *Acinetobacter*
233 *baumannii* international clones II and III in Lima, Peru. *Emerg Microbes Infect*
234 2018;7:119.

- 235 17. **Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ et al.** Outbreak of
236 carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in
237 Curitiba, Brazil. *J Clin Microbiol* 2003;41:3403-3406.
- 238 18. **Bier KES, Luiz SO, Scheffer MC, Gales AC, Paganini MC et al.** Temporal
239 evolution of carbapenem-resistant *Acinetobacter baumannii* in Curitiba, southern
240 Brazil. *Am J Infect Control* 2010;38:308-314.
- 241 19. **Martins N, Dalla-Costa L, Uehara AA, Riley LW, Moreira BM.** Emergence of
242 *Acinetobacter baumannii* international clone II in Brazil: reflection of a global
243 expansion. *Infect Genet Evol* 2013;20:378-380.
- 244 20. **Pagano M, Nunes LS, Niada M, Barth AL, Martins AF.** Comparative Analysis of
245 Carbapenem-Resistant *Acinetobacter baumannii* Sequence Types in Southern Brazil:
246 From the First Outbreak (2007-2008) to the Endemic Period (2013-2014). *Microb*
247 *Drug Resist* 2019;25:538-542.
- 248 21. **Camargo CH, Yamada AY, Nagamori FO, de Souza AR, Tiba-Casas MR et al.**
249 Clonal spread of ArmA- and OXA-23-coproducing *Acinetobacter baumannii*
250 International Clone 2 in Brazil during the first wave of the COVID-19 pandemic. *J*
251 *Med Microbiol* 2022;71:001509.
- 252 22. **Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al.**
253 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an
254 international expert proposal for interim standard definitions for acquired resistance.
255 *Clin Microbiol Infect* 2012;18:268-281.
- 256 23. **Clinical and Laboratory Standards Institute.** *Performance standards for*
257 *antimicrobial susceptibility testing. Thirty-First Edition. CLSI document M100.*
258 Wayne, PA: Clinical and Laboratory Standards Institute; 2021.

259 **24. Food and Drug Administration.** *FDA Drug Safety Communication: FDA warns of*
260 *increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new*
261 *Boxed Warning*; 2013. Available from: [https://www.fda.gov/drugs/drug-safety-and-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warnsincreased-risk-death-iv-antibacterial-tygacil-tigecycline)
262 [availability/fda-drug-safety-communication-fda-warnsincreased-risk-death-iv-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warnsincreased-risk-death-iv-antibacterial-tygacil-tigecycline)
263 [antibacterial-tygacil-tigecycline](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warnsincreased-risk-death-iv-antibacterial-tygacil-tigecycline). Accessed March 3rd, 2023.

264 **25. The European Committee on Antimicrobial Susceptibility Testing.** *Breakpoint*
265 *tables for interpretation of MICs and zone diameters* (Version 11.0. 2021).
266 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf)
267 [Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf) [assessed 13 December 2022].

268 **26. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S.** The population
269 structure of *Acinetobacter baumannii*: expanding multiresistant clones from an ancestral
270 susceptible genetic pool. *PLoS One* 2010;5:e10034.

271 **27. Fragkou PC, Poulakou G, Blizou A, Blizou M, Rapti V et al.** The Role of
272 Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug,
273 Extensively Drug and Pandrug Resistant *Acinetobacter baumannii*: A Systematic
274 Review of Clinical Evidence. *Microorganisms* 2019;7:159.

275 **28. Cherubini S, Perilli M, Segatore B, Fazii P, Parruti G et al.** Whole-Genome
276 Sequencing of ST2 *A. baumannii* Causing Bloodstream Infections in COVID-19
277 Patients. *Antibiotics (Basel)* 2022;11:955.

278

279

280

281

282 **Table 1.** Primers used in this study.

Primer name	Primer sequence (5' – 3')
16S RNA F	AGAGTTTGATCCTGGCTCAG
16S RNA R	GTTGCGCTCGTTGCGGGACT
Cnp60 F ^a	ACTGTA CTTGCTCAAGC
Cnp60 R ^a	TTCAGCGATGATAAGAAGTGG
IMP F	GAAGGCGTTTATGTTTCATAC
IMP R	GTAAGTTTCAAGAGTGATGC
VIM F	GTTTGGTCGCATATCGCAAC
VIM R	AATGCGCAGCACCAGGATAG
NDM F	GGTTTGCGGATCTGGTTTTTC
NDM R	CGGAATGGCTCATCACGATC
OXA-51-like F	CGAAGCACACACTACGGGTGTTT
OXA-51-like R	TTCCCTTGAGGCTGAACAAC
OXA-23 F	GATGTGTCATAGTATTCGTCTG
OXA-23 R	TCACAACA ACTAAAAGCACTG
OXA-58-like F	AAGTATTGGGGCTTGTGCTG
OXA-58-like R	CATCACCAGCTTTCATTTGC
OXA-24 F	ATGAAAAAATTTATACTTCC
OXA-24 R	TTAAATGATTCCAAGATTTTC
ISAbal F	AGTTGCACCTGGTCAATGA
ISAbal R	CATGTAAACCAATGCTCACC
armA F	TGCATCAAATATGGGGGTCT
armA R	GGATTGAAGCCACAACCAAA
rmtD F	GGAAAAGGACGTGGACA
rmtD R	TCCATCGATTCCACAGG
CTX-M F	CGCTTTGCGATGTGCGAG
CTX-M R	ACCGCGATATCGTTGGT
TEM F	GTATCCGCTCATGAGACAATA
TEM R	TCTAAAGTATATATGAGTAACTTGGTCTG
GES F	ATGCGCTTCATTCACGCAC
GES R	CTATTTGTCCGTGCTCAGGA
mcr F	ACCATGCTCCAAAATGCC
mcr R	ATCCATCACGCCTTTTGAGTC
Int1 F	GGGTCAAGGATCTGGATTTTCG
Int1 R	ACATGCGTGTAATCATCGTCTG
INF	GGCATCCAAGCAGCAAG
INB	GGGCAGACTTGACCTGAT
Int2 F	GCGTTTTATGTCTAACAGTCC
Int2 R	AAGTAGCATCAGTCCATCC
GyrA F	AGGACGAACTCAAGCATTCA
GyrA R	GCCAAACAAGCATTCACAAC
ParC F	CGCTCTGTAGCCGAATTTACT
ParC R	CCATCCCAACAGCAATACCT

283 ^a Diancourt *et al.* [26]

284

Table 2. Susceptibility profile and antibiotic resistance genes in the XDR IC2 *A. baumannii*

strains of this study

IC2 strains	Antimicrobial resistance profile	ARGs
AB85	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, MIN, TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB91	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN, TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB92	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN, TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB93	IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, <u>SXT</u> , TET, DOX, <u>MIN</u>	<i>armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB94	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, <u>SAM</u> , TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN, TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB105	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB106	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, <u>MIN</u> , <u>TGC</u>	<i>armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB110	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN, TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>

AB111	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, <u>LEV</u> , SXT, TET, DOX, <u>TGC</u>	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB112	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, <u>MIN</u>	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB113	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, <u>MIN</u>	<i>armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB114	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB115	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, <u>LEV</u> , SXT, TET, <u>DOX</u> , <u>TGC</u>	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB116	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB117	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, MIN	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>
AB118	AMK, GEN, NET, TOB, IPM, MEM, DOR, CAZ, FEP, CTX, CRO, SAM, TZP, TIM, CIP, LEV, SXT, TET, DOX, <u>MIN</u> , TGC	<i>intI1-aacA4-catB8-aadA1-qacEΔ1/sul1; armA; bla_{TEM}; bla_{OXA-66}; ISAbal-bla_{OXA-23}</i>

287 Intermediate resistance are underlined

288

289